Stocks · News reference
Bridgebio Oncology Therapeutics Says BBO-8520 Monotherapy Shows 63% ORR, 100% DCR In 2L+ KRASG12C NSCLC; BBO-11818 And BBO-10203 Monotherapy Data Update Expected In Q4 2026; Expanded BBO-8520 Plus Pembrolizumab Dataset Expected In Mid-2027; BBO-11818 And BBO-10203 Combination Data In CRC And PDAC Expected Mid-2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.